Equity Method Accounting for Common Stock of Oncocyte, at Fair Value (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 08, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Feb. 17, 2017
Closing price per share						$ 1.31	$ 0.62
OncoCyte Corporation [Member]
Common stock at fair value										14,700,000
Fair value on investment	$ 36,500		$ 36,500				$ 20,300
Closing price per share	$ 2.49	$ 2.55	$ 2.49	$ 2.55	$ 3.95		$ 1.38	$ 2.10	$ 4.65
Unrealized (gain) loss on equity method investment in at fair value	$ (21,425)	$ 6,603	$ 16,288	$ (30,816)